UK NEQAS

for

Peptide Hormones and Related Substances

Participants' Handbook

November 2022

UK NEQAS [Edinburgh]
Department of Laboratory Medicine
Royal Infirmary of Edinburgh
Edinburgh EH16 4SA, UK

1. Service provided

Scheme	Analytes
Peptide hormones I	Follicle stimulating hormone (FSH) Luteinising hormone (LH) Prolactin (PRL) and macroprolactin (pilot) Growth hormone (hGH) Anti-Müllerian Hormone (AMH)
Peptide hormones II	Parathyroid hormone (PTH) Adrenocorticotrophic hormone (ACTH) Calcitonin (hCT)
Tumour markers	Alpha-fetoprotein (AFP) Carcinoembryonic antigen (CEA) Chorionic gonadotrophin (hCG)

Maternal serum screening	Down's syndrome (1st trimester)
	    Free β-subunit of hCG (hCGβ).
	    PAPP-A
	Down's syndrome (1st trimester)
	    Dried blood spots (Pilot)
	    Placental growth factor (PLGF) (Pilot)
	
	Down's syndrome (2nd trimester)
	    Alpha-fetoprotein (AFP):
	    Chorionic gonadotrophin (hCG): Intact hCG, total hCG and the free β-subunit (hCGβ).
	    Unconjugated oestriol (UE3)
	    Inhibin A
	Neural tube defects
	    Alpha-fetoprotein (AFP)

Pregnancy testing	Urinary hCG (qualitative) Urinary hCG (quantitative)
Pre-eclampsia markers*	Placental growth factor (PLGF) Soluble fms-like tyrosine kinase 1 (sFlt-1) sFlt-1 / PLGF ratio
Liver fibrosis markers*	Procollagen III amino terminal peptide (PIIINP) Hyaluronic acid Tissue inhibitor of metalloproteinase 1 (TIMP-1) Enhanced liver fibrosis (ELF) score Other liver fibrosis scores

* Established UK NEQAS scheme but not yet put forward for accreditation.

The UK National External Quality Assessment Service (UK NEQAS) for Peptide Hormones and Related Substances [UK NEQAS [Edinburgh]] is part of a network of UK NEQAS Centres providing External Quality Assessment (EQA) for hormones and tumour markers. UK NEQAS [Edinburgh] collaborates closely with related UK NEQAS centres in Birmingham, Glasgow, Guildford and Sheffield.

2. Address for correspondence

UK NEQAS [Edinburgh]
Department of Laboratory Medicine
The Royal Infirmary of Edinburgh
Edinburgh EH16 4SA
United Kingdom

Tel:+44 (0)131 242 6885 (24 hour voice-mail)
Fax: +44 (0)131 242 6882
Scheme e-mail: ukneqas@ed.ac.uk

3. Staff

Director Dr Catharine Sturgeon	Tel: +44 (0)131 242 6885 e-mail: C.Sturgeon@ed.ac.uk
Deputy Director: Mr Nick Unsworth	Tel: +44 (0)131 242 6848
Administrative support Post vacant	Tel: +44 (0)131 242 6849
Technical support Miss Mary Costa and Ms Ewa Drozdzal	Tel: +44 (0)131 242 6843

4. Service objectives

UK NEQAS [Edinburgh] aims to provide

- Professionally-led and scientifically-based EQA schemes with a primarily educational objective.
- Regular distributions of appropriately constituted specimens/
- Rapid feedback of individual participant performance in reports that are comprehensive and readily understood.
- Data on method-related performance.

The UK NEQAS [Edinburgh] laboratory is located within the Department of Laboratory Medicine, Royal Infirmary of Edinburgh, and there is a close working relationship between UK NEQAS and the Department.

UK NEQAS [Edinburgh] may sub-contract some services where appropriate.

5. Service accreditation

All schemes provided by UK NEQAS [Edinburgh] except those for Liver Fibrosis Markes and Pre-eclampsia Markers are currently accredited by the United Kingdom Accreditation Service [UKAS Reference No 8505]. The next on-site inspection will take place in November 2022.

Further information about standards for the accreditation of EQA schemes may be obtained from UKAS. (Contact details in Appendix 4).

6. Enrolment procedures

Intending participants can access registration forms and other information on the UK NEQAS [Edinburgh] website (www.edqas.org) or can contact the unit to request these. Relevant documents include:

- Registration forms
- Participants' handbook
- Distribution schedule

Participation begins at the first distribution following receipt of completed registration forms. Enrolment may take place at any time of the year.

The majority of participants are UK NHS clinical service laboratories, but all laboratories - including non-UK, research and IVD manufacturers' laboratories - are most welcome to participate. [See Section 8.2]

All UK clinical service laboratories must agree to theJoint Working Group (JWG) Conditions of Participation (Appendix 1).

Participation of non-UK laboratories may be subject to the availability of suitable specimen transport.

Manufacturers are welcome to participate fully in the same way as clinical service laboratories (receiving samples and returning results) or on an 'information only' basis. They may also register methods under development on an anonymous basis.

7. Charges and charging period

The financial year is from 1st April to 31st March, with a price list prepared annually and available on request. Participants will be advised of each year's charges in advance. Participation is deemed to be continuous so participants do not need to renew their subscription annually. Participation may begin at any time during the year. Charges for participation for part of the year are generally *pro rata*. Refunds of subscription charges are only payable under exceptional circumstances.

Pilot schemes are schemes that are in development and have not yet been put forward for accreditation. No charge is made for participation in pilot schemes.

8. Service organisation

8.1 Laboratory Code Numbers

Each participant is assigned a unique code number, which is common to most UK NEQAS schemes. A participant may be assigned more than one code number if more than one instrument or method is in use for a single analyte in a laboratory. Second registrations may be free of charge.

Please always include your laboratory number in the subject line subject line of all e-mails to us. This helps facilitate timely response.

8.2 Method codes

Methods are normally referred to by full name, but may occasionally be abbreviated. Abbreviations are defined in the monthly reports.

Please check your method/code in all communications and inform us of any changes and the distribution number at which the change came into effect.

Manufacturers should note that in the interests of commercial confidentiality, a method under development can be temporarily assigned a "Method development" code until its general release, when it will be assigned an appropriate permanent code.

8.3 Confidentiality

The fact of participation, raw data, performance scores and all reports generated by UK NEQAS [Edinburgh] are confidential between the individual laboratory and UK NEQAS staff. Performance scores (and some relevant raw data) may be shared with the relevant Advisory Panel under defined circumstances (Appendix 1) as part of the routine reporting of persistent poor performance. Reports may also be shared by participants with local management, regional QA officers, accrediting bodies, and suppliers of equipment and reagents if they wish. Where appropriate and necessary, UK NEQAS staff may also divulge the information but only with the participant's written permission. Any other use must be approved by the UK NEQAS Scheme Director in advance.

9. Service operation

9.1 Specimens

All serum, plasma, dried blood spot and urine specimens are of human origin. Specimens may be "spiked" with standards or other sources of

analyte to give appropriate concentrations. Specimens are stored below -25°C prior to issue. During pool preparation, serum, plasma and urine pools may require clarification by filtration through glass wool.

ProClin™ 200 (0.5% v/v) is added as a bacteriocide to all pools that will be issued as liquid specimens. Preservative is not added to lyophilised pools (Peptide II scheme).

The volume provided is 0.5-1.0 mL per specimen, depending on the analyte. Specimens are dispatched at ambient temperature. Specimen homogeneity is regularly assessed.

The number of specimens issued per distribution varies depending on the analyte and is documented in the following table. Extra specimens may be issued if required.

Low concentration specimens are issued regularly to confirm "baseline security" which is especially important for some analytes including the serum tumour markers and growth hormone. Such specimens are generally excluded from assessment of cumulative performance.

Specimens may occasionally include clinically relevant additions (e.g. biotin, heterophilic antibodies) to highlight to participants potential analytical and interpretative pitfalls and form an important contribution to the educational remit of the schemes. These are also usually excluded from performance assessment.

9.2 Safety precautions in handling specimens

Pools are prepared from donations that have been tested either individually or as pools of less than twenty individual samples (where no individual specimen has been diluted more than 20 times) and have been confirmed to be negative for antibodies to human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and antibodies to hepatitis C virus (HCV).

However, EQA specimens should always be handled with the same precautions that are normally adopted in the handling of patient specimens.

Where it is not possible to test individual donations, one of the following alternative procedures may be adopted

a) The material may be virologically tested in pools of no more than twenty individual donations.
b) Material may be issued untested (participants are always made aware of this).

9.3 Schedule of specimen distribution

Specimens are distributed by first class post every 4 weeks (8 weeks for the Peptide II scheme), together with a results sheet. Electronic copies of the reports on the previous distribution are then made available to all participants on the results website. Express mail or courier delivery is available to overseas participants at additional cost. Several analytes share specimens, as indicated in the following table. The Distribution Schedule is on the scheme website at www.edqas.org.

Combinations of analytes and number of specimens per distribution.

Scheme	Analyte(s)	Specimens per Distribution	Distributions per annum
Peptide I	FSH, LH, AMH, prolactin Growth hormone	4 4	12
Peptide II	PTH ACTH Calcitonin	3 3 3	6
AFP, CEA and hCG	AFP, hCG, CEA	4	12
Pregnancy testing	Qualitative & quantitative hCG	2	12
Maternal serum screening	NTD (AFP) Second trimester Down's (AFP, hCG, UE3, inhibin) First trimester Down's (hCGβ, PAPP-A) First trimester Down's (hCGβ, PAPP-A) using dried Blood Spots [Pilot] (hCGβ, PAPP-A)	3 3 3 5 3	12 12 12 12 3
Pre-eclampsia markers*	PLGF sFlt-1	3 3	12 12
Liver fibrosis markers*	PIIINP Hyaluronic acid TIMP-1 ELF score Other fibrosis scores	3	12

* Established UK NEQAS scheme but not yet put forward for accreditation.

10. Processing UK NEQAS samples in your laboratory

10.1 Receipt and analysis

UK NEQAS samples are intended to monitor laboratory performance on routine patient specimens. **They should be treated in exactly the same way as routine clinical samples from when they first arrive in the laboratory.**

Please contact us immediately if you receive incorrect or damaged specimens, and replacements will be sent.

10.2 Return of results

Results must be returned within 3 weeks of the date of specimen issue if they are to be included in the monthly report and numerical results always reported as if for clinical results. Results should be submitted via the UK NEQAS web based results service at https://results.ukneqas.org.uk/ A password, available from UK NEQAS, is required for data entry via the website.

Results will be accepted if posted, faxed, e-mailed or telephoned. Written submissions must be clear and state laboratory and distribution numbers.

EQA results should be submitted as for patient results, e.g., to the same number of decimal places. "Less than" and "greater than" results should also be submitted as for clinical samples.

10.3 Failure to return results

If you make no response to a distribution by the due date your report will state "This laboratory has failed to return any results for this distribution". Regular participation is important if adequate data are to be obtained, and is one of the criteria of good performance.

If you fail to return results for three consecutive distributions, you will be regarded as having poor performance.

If you are unable to report results on a distribution, results should be submitted as "NULL" on the Results website and an explanation provided in the Comments box. A report will then be uploaded in the usual way. **Entries such as "XPL" will not be interpreted correctly by the Results website and we will not know that an unsuccessful attempt has been made to submit results.**

10.4 Late returns

We always accept and process late results provided there is a legitimate explanation (e.g. delayed arrival of specimens). If you return results after the due date they will be added to your cumulative record of performance and you will be sent a full report. Reports may be flagged as "Late" at the discretion of the Scheme Director.

10.5 Errors and their correction

Causes of errors (which may or may not be classified as outliers) include

- Assaying the wrong samples.

- Assaying the right samples in the wrong order.

- Incorrectly transcribing laboratory results from computer systems or worksheets to results documents or the web entry system.

- Using incorrect units and/or conversion factors.

- Technical errors, e.g. incorrect reconstitution, incomplete mixing after thawing, faulty sampling/pipetting etc.

Such errors can be corrected but the error and the cause identified will be recorded separately and results may be marked as amended.

Amendments prior to reporting deadline Amendments can be made on the Results Website while data submission is open. Amended copies of results submitted by post should be clearly marked as such with the change unambiguously highlighted.

Amendments after the reporting deadline Please e-mail us to explain the issue. Results can usually be amended and an updated report produced.

Amendments after receipt of reports These should be reported in writing with an explanation of the reason for any amendment. Where investigation reveals the cause of the error, and repeat results are available, correction of the original results is permissible. However, the fact that you reported incorrect results will be recorded. Each incorrect result is counted as one error. Transcription errors in the Pregnancy Testing Scheme are generally not corrected because such errors are likely to reflect what happens in clinical practice.

10.6 UK NEQAS [Edinburgh] errors

If you suspect that we have made an error please let us know immediately.

We review all such errors carefully and it is important that we know about them so that we can audit and improve our service. Errors made by UK NEQAS [Edinburgh] will be corrected without penalty to the laboratory. Corrected reports will be accompanied by an apology.

10.7 Status of reports

The most recent versions of your report is always that uploaded to the Results website. The report will include results that have been received or amended after the first scheduled analysis so there may be minor differences in numerical details, e.g. the number of participants returning results. If it has been necessary for any reason to re-analyse and re-upload all reports for a given distribution (e.g. due to an error identified

subsequent to the first upload) this will be clearly stated and the reason explained in the Comments section to the report.

11. Performance assessment

11.1 Target values

UK NEQAS attaches great importance to validation of target values, rather than simply accepting consensus means as the "correct" result.

For most schemes in which quantitative results are reported, the all-laboratory trimmed mean (ALTM) is used as the target, but in several schemes grouped-method means are used as they are scientifically more appropriate (e.g. in the schemes for PAPP-A and UE3). Assigned values are selected as the best estimate of the true value.

Target values should be accurate and stable, but this is difficult to test for peptide hormones and tumour markers, where the reference methods required for metrological traceability are generally not available. However some evidence for the validity of the consensus mean target values can be obtained by testing their recovery, linearity and stability regularly.

Specialised schemes may have different targets. For example, achieving consensus in the Pregnancy Testing scheme requires that ≥80% of participants using methods with the same claimed detection limit agree.

11.2 Uncertainty of measurement for quantitative tests

The standard uncertainty (U) of the consensus mean target value is calculated using the following formula:

$$U = 1.25 \times SD / \sqrt{n}$$

where SD is the standard deviation and n the number of results.

The uncertainty of measurement is stated for each pool on the analyte-specific page of personalised participant reports. Provided the standard uncertainty is <0.3 x the SD, the uncertainty of the consensus mean should have negligible effect on assessment of performance.

11.3 Calculation of analytical performance scores for schemes in which quantitative results are reported

Laboratory performance is reported as BIAS, which is the mean percentage deviation from target, and VAR, which measures the consistency of bias. BIAS and VAR are updated on a rolling basis across six distributions, i.e. the oldest data are removed from the laboratory record as new data are added. Note that some samples (e.g. those of low concentration or those containing added exogenous analyte) are routinely excluded from these calculation. A minimum of ten usable values is required to compute BIAS and VAR.

11.4 Calculation of analytical performance scores for schemes in which qualitative results are reported

Results may be reported as "positive" (P), "negative" (N) or "equivocal" (E). The target for scoring purposes is the consensus of results reported by all users of the relevant method grouping. Each result is given a score according to its relationship to the consensus. Laboratory performance is then calculated as the sum of these performance scores over the last six distributions. A minimum of six usable results are required.

11.5 Calculation of analytical performance scores for risk estimates in the maternal serum screening

Laboratory performance is reported as

1. **Running risk score (RRS)** Designed to be analogous to BIAS. RRS is the median of risk scores (RS) recorded during the time window (most recent six distributions). At least ten risk scores are needed to calculate the RRS, which should be close to zero.

2. **Non-parametric estimate of the SD of RRS (SDRRS)** Designed to be analogous to VAR. SDRRS is the non-parametric standard deviation (SD) of the RRS. Calculated as the median of the absolute differences between RS and RRS, the SDRRS should be close to zero.

12. Performance criteria

12.1 Limits for acceptable performance

Limits for acceptable performance are approved by the National Quality Assurance Advisory Panel for Chemical Pathology (NQAAP) in consultation with the Specialist Advisory Group for Immunoassay.

The limits reflect clinical requirements, the state of the art for the analyte, and the need for regular quality assurance monitoring.

The criteria include acceptable limits for BIAS and VAR, and for return rate and are summarised in Appendix 2. BIAS and VAR criteria have not been established for all analytes and no performance criteria have been defined for the running risk scores (Maternal Serum Screening) or the quantitative scores (Pregnancy Testing).

The monthly reports include figures to show individual performance in relation to the relevant criteria. Laboratories should aim to maintain performance within these limits and are invited to contact us if problems appear to be developing, whether in analytical performance or in the ability to maintain regular returns.

12.2 Persistent poor performance and action taken

UK clinical laboratories are subject to NQAAP surveillance and should be aware of the conditions of participation (Appendix 1).

A laboratory is considered to be a persistent poor performer for a given analyte if

• Its cumulative performance is outside the prescribed limit for BIAS and/or VAR for three consecutive months,

or if

• It fails to return results for three consecutive months.

We will generally make informal contact with any participant falling into the above categories. If performance fails to improve, the Chairman of the appropriate NQAAP will be notified. Advice is then offered to the head of the laboratory in writing or, where appropriate and rarely, following a visit to the laboratory from a NQAAP member or other appropriate expert.

12.3 Suspected collusion

Clearly participation in external quality assessment is most beneficial when specimens are treated in the same way as patient specimens (e.g. assayed only once and without conferring with any other laboratory).

All submitted results are inspected by UK NEQAS staff prior to analysis using dedicated checklists. Any suspicion of collusion (e.g. identical sets of results reported) will be investigated thoroughly and copies of the relevant original analyser print-outs of results requested.

12.4 Disclosure of assigned values prior to data analysis

Details of specimen composition and/or expected results are not disclosed to participants until analysis of the results is completed and reports finalised. Rarely, and only in exceptional circumstances and at the discretion of the Scheme Director, these details may be disclosed to individual participants in advance, e.g. where a performance issue that may adversely affect patient results has been identified and urgent independent confirmation of a potential problem is required.

13. Reports and their interpretation

All participants can view their reports on the UK NEQAS Results Website at https://results.ukneqas.org.uk/. A password is required and can be obtained from UK NEQAS [Edinburgh]. Reports on the website are generally those obtained at the time of the initial analysis of the results submitted unless otherwise notified to participants, e.g. by e-mail. Reports rarely have to be reissued but if this is necessary it is clearly indicated in the box at the bottom of the first page of the new report and/or in the Comments section of the report. Correction of errors notified by individual participants and requiring reanalysis may change the target values very slightly but this is unlikely to influence interpretation.

13.1 Quantitative schemes (BIAS and VAR scoring)

13.1.1 Overview

The report format is similar to that used in many other UK NEQAS schemes and contains the following sections:

A summary. This shows your performance for all analytes on the current distribution, and your current cumulative BIAS and VAR. This may be all you need to consult if performance is stable.

Details of performance for each analyte. This shows method performance on the current distribution, and tabulates all results for an individual participant for the most recent six distributions. Consult this section if you need to review your performance, or if you need information on method performance.

Comments. This section amplifies the data in the sections above, or may describe the results of surveys, e.g. interpretation of results. Summaries of recent literature are supplied in most schemes.

13.1.2 Interpretation of BIAS and VAR cumulative performance data

Calculation of BIAS and VAR by combining results from different pools at different concentrations over six distributions is designed to maximise use of the data, but introduces certain constraints in the interpretation of these performance statistics as illustrated in the examples below. Interpretation of BIAS and VAR is always assisted by examining the "Analysis of Bias" table which shows performance by pool and distribution (page 18) over a six month window. The figures may be interpreted as follows:

Low BIAS, low VAR The assay is precise and is giving results close to the target value in the concentration range assessed. This represents desirable performance, assuming accuracy of the target value.

Low BIAS, high VAR There is wide scatter of bias on individual specimens, although the mean ratio to the target value is near unity.

There are several sources of high variability, including

1. Between- and within-assay imprecision
2. Dose-related differences in bias
3. Pool-related differences in bias

The "Analysis of Bias" table will help to identify which, if any, of the above is most relevant. As the VAR essentially provides an indication of the confidence with which the mean BIAS can be estimated, it would be wrong under these circumstances to be too complacent about low BIAS.

High BIAS, low VAR The assay is clearly biased relative to the target value, the ratio of individual results to ALTM (or GLTM) results being relatively constant over the concentration range assessed. Common causes of this include errors in standardisation (e.g. calibrator change, wrongly prepared or degraded calibrators), errors in conversion of results

to the units used by UK NEQAS (e.g. wrong factor, wrong mathematics) and differences in assay specificity.

High BIAS, high VAR There is a wide scatter of deviation from target on individual specimens, superimposed on a shift from unity in the mean ratio of results to the ALTM (or GLTM). The above comments on high VAR apply. The BIAS cannot be reliably estimated while the VAR remains high, and elimination of the sources of variability should be a first priority.

Note that if an assay is biased and steps are taken to correct this, VAR will remain high temporarily while the gradually improving BIAS passes through the six distribution window.

13.2 Risk estimates (maternal serum screening

The report is similar in style to the "BIAS and VAR" report described above and contains the following sections:

1. Information on the specimens in the current distribution. A histogram shows the distribution of risk estimates returned by all participants using the relevant combination of analytes.

2. Summary data for the six most recent distributions. All the relevant risk estimates and their targets are shown in a table, and trends in cumulative risk scores are shown. [Multiples of the median (MoMs) are analysed but degrees of extremeness (DoEs) are not.]

13.2.1 Interpretation of cumulative risk scores

The target for scoring risk estimates is simply the median of all estimates returned by participants using the relevant combination of analytes. This target is pragmatic and cannot be validated. With this proviso, participants should have running risk score (RRS) and standard deviations of running risk score (SDRRS) close to zero. The figures may be interpreted as follows:

High RRS, low SDRRS

Risk estimates are biased to the target values, but consistent.

Near-zero RRS, high SDRRS

On average, risk estimates are close to the targets, but their scatter is wide, suggesting some imprecision in the estimation of risk.

High RRS, high SDRRS

Risk estimates may be both imprecise and inaccurate.

13.3 Pregnancy Testing

The reports are organised by analyte, with no summary page. Participants reporting qualitative results receive a personalised report which includes the following information:

Panel 1.   Distribution number, date of return, and lab number.

Panel 2.   Specimen and pool numbers for the current specimens together with a brief description of their content.

Panel 3.   Pie charts showing for each specimen the % distribution of results [positive (P), negative (N) or equivocal (E)] and the consensus results. Individual laboratory results, and the score for this distribution, are also shown.

Panel 4.   A single pie chart showing the percentage of usable specimens distributed (P, N and E) during the previous six months, followed by pie charts showing the laboratory's cumulative data for each type of specimen (P, N and E).

Panel 5.   A graph showing the trends in cumulative interpretation score over the previous twelve months. [The cumulative

See pages 20 and 21 for examples of UK NEQAS risk estimate reports, with explanatory notes.

See pages 22 and 23 for examples of Pregnancy Testing reports, with explanatory notes.

score at each distribution is based on results for the previous six distributions.] There is also a table tabulating the laboratory's performance for each specimen.

Panel 6.   A paragraph explaining the scoring system in use. [See page 28 for details.]

Participants reporting quantitative results receive a summary report similar to that in the serum hCG scheme. [These reports are for information only and results are not scored.]

A separate section tabulating all results received from users of all methods accompanies the personalised report.

13.3.1 Interpretation of cumulative interpretation scores

This score for qualitative results provides a measure of the level of agreement of individual results (positive, negative or equivocal) with the consensus result, averaged over six distributions. A score of zero shows complete agreement with the consensus. Positive scores suggest lack of agreement of the results with the consensus.

14. Previously issued specimens

Aliquots of previously issued specimens with target values can usually be provided to participants wishing to check existing assays or to evaluate new ones. An additional charge will normally not be made for such specimens. Specimens may also be available to manufacturers wishing to trouble-shoot existing assays or to evaluate new ones. A charge may be made for this service.

15. Customised reports

Special reports may be prepared to meet specific requirements, e.g.

Method reports which can assist participating manufacturers in monitoring their products and participants evaluating methods or during tendering.

Laboratory subgroup reports for regional QA or Audit activities

16. Service development and scientific support

UK NEQAS [Edinburgh] is advised by the Specialist Advisory Group for Immunoassay and the Specialist Advisory Group for Maternal Serum Screening, which provide scientific advice. For current membership of these groups please see Appendix 3.

17. Confidentiality

The fact of participation, raw data, performance scores and all reports generated by the scheme are confidential between the individual laboratory and UK NEQAS staff. Performance scores may be shared with the relevant Advisory Panel under defined circumstances. Reports may also be shared by participants with local management, regional QA officers, accrediting bodies and suppliers of equipment and reagents if they wish. Where appropriate, UK NEQAS staff may also divulge the information but only with the participant's written permission except in the case of persistent poor performance that cannot be resolved through dialogue between scheme staff and the participant. In this case, the identity of the laboratory will be made available to members of the National Quality Assurance Advisory Panel (NQAAP) and the Joint Working Group (JWG) as described in the Conditions of EQA Scheme Participation [Appendix 1.].

UK NEQAS [Edinburgh] reports are copyright and may not be copied, distributed, published or used for publicity and promotion in any form without the written consent of the Scheme Director on each and every occasion.

18. Comments and complaints

Comments about any aspect of the service, whether scientific or operational are welcome. In the event of complaints about day to day operational matters, please provide your laboratory number, scheme, distribution number and specimen number(s). Problems will be addressed as soon as possible.

Complaints can also be referred to any member of the Specialist Advisory Groups (Appendix 3).

UK NEQAS [Edinburgh] is always pleased to receive suggestions from participants about ways in which the service provided could be improved.

19. Annual review

An *Annual Review* of the UK NEQAS results for the previous year, including analysis of long-term trends in participation and method performance, is prepared each year and considered by the relevant Specialist Advisory Group.

20. UK NEQAS Reports and Performance Calculations – Illustrated examples

TERMINOLOGY

ALTM	The All Laboratory Trimmed Mean, which is the geometric mean of the entire set of trimmed results for a specimen.
BIAS	The geometric mean of the trimmed deviations of your laboratory's results from their targets for all usable specimens for which you have returned results during the current six months.
CUMULATIVE INTERPRETATIVE SCORE (Pregnancy testing)	The sum of your scores over the last six distributions.
DEVIATION (dev'n)	The difference between your result and the target result, expressed as a percentage of the target.
DISTRIBUTION	A group of specimens in a particular scheme that are sent together to each participating laboratory.
GCV	The geometric coefficient of variation of the results in a set or sub-set of results.
GLTM	The geometric mean of a sub-set of the trimmed results for a specimen. The sub-set may be a group of inter-related methods.
LSD	The linear estimate of the standard deviation of the log transformed, trimmed results.
MAXIMUM NUMBER OF RESULTS	Number of usable specimens issued in the current six months.
MLTM	The geometric mean of the trimmed results for a specimen observed by users of one method.
NUMBER OF RESULTS	Number of usable specimens for which your laboratory has returned numerical results.
OUTLIER (BETWEEN-LABORATORY, WITHIN-SPECIMEN)	A result that is more than three LSD's from the appropriate target. These outliers demonstrate an inability to agree with your peers.
OUTLIER (WITHIN-LABORATORY, BETWEEN-SPECIMEN)	A result that has a deviation that is more than three SD's from your cumulative BIAS. These results are rather less significant, as they depend on your VAR. A relatively small deviation would be flagged if you have a low VAR, but would not be flagged if your VAR were high.

POOL	A bulk preparation of serum usually prepared from several individual donations.
RS (Risk score)	A score representing the deviation of your risk estimate from consensus.
RRS	The median of your risk scores (RS) over the last six distributions.
SAMPLE	An alternative term for specimen.
SCORE (Pregnancy testing)	A score representing the deviation of your result (positive, negative or equivocal) from consensus.
SDRRS	The standard deviation of your RRS. It is an estimate of spread of risk estimates.
SPECIMEN	An aliquot of a given pool. The same pool may be issued on more than one occasion with different specimen numbers.
TRANSFORMATION	The process of converting results to their natural logarithms in order to correct for skew of the raw distribution prior to statistical analysis.
TRIMMING	The effect of aberrant results that may be present is minimised by trimming the data prior to statistical analysis. The chosen method is that of Healy, which involves trimming of the lowest and highest 5% of results, (see Page 18). Note that trimmed results are not necessarily outliers.
USABLE SPECIMEN	A specimen that has no unusual or unacceptable features will be deemed to be usable for the calculation of cumulative BIAS and VAR. Unusable specimens include those with analyte concentrations near the detection limits of the assays and those with added interfering substances.
VAR	The variability or GCV of the BIAS, or scatter of the deviations of your results from target for all usable specimens in the six distributions to date. VAR reflects imprecision, but is affected by dose or specimen related bias.

UK NEQAS for Peptide Hormones					Laboratory :
Distribution : 497			Date : 15-Jun-2021		Page 1 of 19
UK NEQAS [Edinburgh] Distribution Summary					Roche 1

FSH (U/L IRP 78/549)	G501 J248	G502 J253	G503 J254	G504 J255	G505 J256	Your method is Roche Elecsys E170, e601, e602, e801
Your result	16.2	5.5	7.0	46.9	6.6	Your BIAS (%) is +0.5
Target (ALTM)	16.3	5.4	7.0	46.5	6.7	Your VAR (%) is 1.7
Your specimens bias(%)	-0.5	+2.1	-0.1	+0.8	-1.0	

LH (U/L IS 80/552)	G501 J248	G502 J253	G503 J254	G504 J255	G505 J256	Your method is Roche Elecsys E170, e601, e602, e801
Your result	19.8	6.6	5.3	26.7	22.2	Your BIAS (%) is +22.4
Target (ALTM)	16.5	5.1	4.1	22.1	19.5	Your VAR (%) is 4.0
Your specimens bias(%)	+20.1	+28.5	+30.8	+20.8	+14.0	

Prolactin (mU/L IS 84/500)	G501 J248	G502 J253	G503 J254	G504 J255	G505 J256	Your method is Roche Elecsys E170, e601, e602, e801
Your result	722	212	204	200	917	Your BIAS (%) is +20.5
Target (ALTM)	623	175	175	170	779	Your VAR (%) is 4.0
Your specimens bias(%)	+15.9	+21.1	+16.8	+17.4	+17.8	

Monomeric prolactin (mU/L IS 84/500)	G501 J248	G502 J253	G503 J254	G504 J255	G505 J256	Your method is Roche Elecsys E170, e601, e602, e801
Your result	600				867	Your BIAS (%) is +20.0
Target (ALTM)	488	150	145	146	692	Your VAR (%) is 4.2
Your specimens bias(%)	+23.0				+25.2	

Post-PEG recovery (%)	G501 J248	G502 J253	G503 J254	G504 J255	G505 J256	Your method is Roche Elecsys E170, e601, e602, e801
Your result	83				95	Your BIAS (%) is +6.7
Target (ALTM)	74	84	81	81	84	Your VAR (%) is 6.2
Your specimens bias(%)	+12.4				+13.3	

Macroprolactin interpret'n (N, E or P)	G501 J248	G502 J253	G503 J254	G504 J255	G505 J256	

Results for the current distribution (for all analytes for which you are registered) showing:
- Pool and specimen numbers
- Concentration units
- Your results
- Target results
- Your specimen bias (% deviation from the target)

Cumulative statistics from the last six distributions showing:
- Your method
- Your cumulative bias from the target (BIAS)
- The cumulative variability (scatter) of your bias (VAR)

Pools that have been excluded for the calculations of the cumulative statistics, and other general information.

Pool J254 has been excluded from all calculations of the cumulative statistics for AMH and Pool W178 has been exclude for all calculations for growth hormone.

UK NEQAS for Peptide Hormones	Laboratory :
Distribution : 497 Date : 15-Jun-2021	Page 2 of 19
UK NEQAS [Edinburgh] Cumulative Summary	Roche 1

These BIAS and VAR plots are intended to give you a graphical representation of your performance relative to that of all other participants.

Your own, current BIAS and VAR are marked with an "X". Data for other users of your method are also plotted individually if less than ten laboratories use it. Otherwise, your method performance is shown by a shaded box bounded by the 5th and 95th centiles of BIAS and VAR. Similarly, an open box with the same bounds is plotted for All Participants.

The dotted lines on the graphs for analytes expressed in concentration units and in MoMs represent the limits of acceptable performance defined by the National Quality Assurance Advisory Panel for Chemical Pathology.

FSH
Your method is Roche Elecsys E170, e601, e602, e801
Your BIAS is +0.5% and VAR is 1.7%

- ⊗ Your lab
- ☐ Overall (n=211)
- ☐ Your method (n=98)
- ▨ Your submethod (n=92)

LH
Your method is Roche Elecsys E170, e601, e602, e801
Your BIAS is +22.4% and VAR is 4.0%

- ⊗ Your lab
- ☐ Overall (n=212)
- ☐ Your method (n=99)
- ▨ Your submethod (n=92)

Prolactin
Your method is Roche Elecsys E170, e601, e602, e801
Your BIAS is +20.5% and VAR is 4.0%

- ⊗ Your lab
- ☐ Overall (n=226)
- ☐ Your method (n=107)
- ▨ Your submethod (n=100)

Monomeric prolactin
Your method is Roche Elecsys E170, e601, e602, e801
Your BIAS is +20.0% and VAR is 4.2%

- ⊗ Your lab
- ☐ Overall (n=29)
- ☐ Your method (n=18)
- ▨ Your submethod (n=16)

Post-PEG recovery (%)
Your method is Roche Elecsys E170, e601, e602, e801
Your BIAS is +6.7% and VAR is 6.2%

- ⊗ Your lab
- ☐ Overall (n=28)
- ☐ Your method (n=16)
- ▨ Your submethod (n=14)

Growth Hormone
Your method is Roche Elecsys E170, e601, e602, e801
Your BIAS is +9.6% and VAR is 12.4%

- ⊗ Your lab
- ☐ Overall (n=76)
- ☐ Your method (n=17)
- ▨ Your submethod (n=14)

Limits of acceptable BIAS and VAR as defined by NQAAP.

Your lab

All methods

Your method (and sub-method if applicable)

Owned and operated by NHS Lothian, UK NEQAS [Edinburgh] is located in the Dept of Laboratory Medicine, Royal Infirmary, Edinburgh EH16 4SA, UK. For scope of scheme accreditation, please see UKAS website [Ref 8505]. Scheme website: edqas.org. Results website: https://results.ukneqas.org.uk

© These data are confidential. In case of queries, please contact the Scheme Organiser, Dr Cathie Sturgeon, who authorised issue of this report on the date below. Phone: +44(0)131 242 6885. Fax: +44(0)131 242 6882. E-mail: ukneqas@ed.ac.uk   Published at 18:45 on Thursday 24 June 2021

UK NEQAS for Peptide Hormones

Distribution : 497	**Date : 15-Jun-2021**
Analyte : FSH (U/L IRP 78/549)	

UK NEQAS [Edinburgh]

Laboratory :

Page 3 of 19

Roche 1

Spec.	Pool	Pool description
G501	J248	Pool of normal female serum.
G502	J253	Pool of normal human serum.
G503	J254	Pool of normal male serum.
G504	J255	Pool of normal post-menopausal serum.
G505	J256	Pool of normal human serum.

☐ All methods
◩ Roche Elecsys
■ E170, e601, e602, e801

Your BIAS (%) is +0.5

Your VAR (%) is 1.7

Your method is :
Roche Elecsys
E170, e601, e602, e801

Specimen : G501

	n	Mean	GCV	Outl.
All methods	212	16.3	7.6	4
Abbott Alinity	15	15.2	4.9	0
Abbott Architect	34	15.0	5.1	0
Beckman Access	14	17.4	6.5	0
DxI	14	17.4	6.5	0
Roche Elecsys	98	16.3	3.1	0
E170, e601, e602, e801	91	16.3	3.0	0
Siemens A Centaur	28	17.8	5.9	0
Siemens Atellica	9	18.8	8.0	1

Your result 16.2
Your target 16.3
Your deviation (%) -0.5
Standard Uncertainty 0.11

Specimen : G502

	n	Mean	GCV	Outl.
All methods	212	5.4	9.8	5
Abbott Alinity	15	4.8	4.9	0
Abbott Architect	34	4.7	4.4	2
Beckman Access	14	5.4	8.2	0
DxI	14	5.4	8.2	0
Roche Elecsys	98	5.6	3.5	0
E170, e601, e602, e801	91	5.6	3.4	0
Siemens A Centaur	28	5.7	6.5	0
Siemens Atellica	9	6.2	8.8	1

Your result 5.5
Your target 5.4
Your deviation (%) +2.1
Standard Uncertainty 0.05

Specimen : G503

	n	Mean	GCV	Outl.
All methods	212	7.0	10.4	4
Abbott Alinity	15	6.5	3.3	0
Abbott Architect	34	6.2	5.5	1
Beckman Access	14	7.8	7.1	0
DxI	14	7.8	7.1	0
Roche Elecsys	98	7.1	3.0	1
E170, e601, e602, e801	91	7.1	3.0	1
Siemens A Centaur	28	7.7	7.1	0
Siemens Atellica	9	8.6	7.0	0

Your result 7.0
Your target 7.0
Your deviation (%) -0.1
Standard Uncertainty 0.06

Specimen : G505

	n	Mean	GCV	Outl.
All methods	212	6.7	15.9	1
Abbott Alinity	15	6.1	2.9	0
Abbott Architect	34	5.9	5.1	1
Beckman Access	14	7.6	10.9	0
			10.9	0
			3.7	0
			3.5	0
Siemens A Centaur	28	6.7	5.9	0
Siemens Atellica	9	9.0	8.5	0

Your result 6.6
6.7
-1.0
0.09

All pools have been included in all calculations of the cumulative statistics.

Callout: Each column shows your result, the target value and % bias for each specimen in a single distribution.

Callout: Pools listed in order of concentration. ( ) indicates pool excluded from statistics. [ ] indicates type of pool.

Pool (exclusion) [Type]	Distribution 492 26-Jan-2021 result	target	%bias	Distribution 493 23-Feb-2021 result	target	%bias	Distribution 494 23-Mar-2021 result	target	%bias	Distribution 495 20-Apr-2021 result	target	%bias	Distribution 496 18-May-2021 result	target	%bias	Distribution 497 15-Jun-2021 result	target	%bias
J245 [B]										1.9	1.9	+0.5						
J234 [B]	3.4	3.4	+0.8															
J252 [B]													3.9	3.8	+2.0			
J249 [B]													4.8	4.8	-1.0			
J253 [B]																5.5	5.4	+2.1
J250 [B]													5.5	5.4	+1.7			
J221 [B]				5.7	5.7	-0.0												
J246 [B]										5.7	5.7	+0.5						
J238 [B]	5.9	5.9	-0.6	5.9	6.0	-1.0												
J230 [B]				5.8	5.9	-0.9												
J256 [B]																6.6	6.7	-1.0
J251 [B]													6.6	6.7	-0.9			
J237 [X,B]	7.1	6.8	+4.8															
J242 [B]							7.1	6.9	+2.3									
J254 [B]																7.0	7.0	-0.1
J247 [B]										9.4	9.1	+3.5						
J239 [B]							10.2	9.9	+2.7									
J244 [B]										10.2	10.3	-0.7						
J222																		
J248 [B]													16.3	16.4	-0.6	16.2	16.3	-0.5
J228 [B]							21.1	20.5	+3.0									
J240 [B]							35.1	34.9	+0.6									
J241 [B]							41.3	40.8	+1.3									
(J236) [X,B]																		
J255 [B]																46.9	46.5	+0.8
J235 [B]																		
J243 [B]							78.4	79.8	-1.7									

	Distribution 492	Distribution 493	Distribution 494	Distribution 495	Distribution 496	Distribution 497
Method	Roche Elecsys	Roche Elecsys	Roche Elecsys	Roche Elecsys	Roche Elecsys	Roche Elecsys
Mean bias	+1.5	-0.7	+2.0	+0.4	+0.2	+0.3
Lot number	451650.0	451650.0	451650.0	451650.0	451650.0	451650.0
BIAS (%)	+2.4	+1.8	+1.8	+1.2	+0.5	+0.5
VAR (%)	2.2	2.4	2.4	2.2	1.6	1.7

B   Base pool, no additions made.
X   Exogenous hormone added (IRP, IS, etc.)

Callout: Your method, monthly mean % deviation, cumulative BIAS and VAR.

Callout: Trends in your BIAS and VAR.

Your cumulative BIAS versus [...]
Your current BIAS is +0.5%

Your cumulative [...]
Your current VAR is 1.7%

Callout: BIAS and VAR of major methods.

BIAS : Method Median, IQR and range

VAR : Method Median, IQR and range

		G501			G502			G503			G504			G505		
	n	Mean	GCV	Outl.	Mean	GCV	Outl.	Mean	GCV	Outl.	Mean	GCV	Outl.	Mean	GCV	Outl.
All methods	212	16.3	7.6	4	5.4	9.8	5	7.0	10.4	4	46.5	9.3	7	6.7	15.9	1
Abbott Alinity	15	15.2	4.9	0	4.8	4.9	0	6.5	3.3	0	43.2	3.1	0	6.1	2.9	0
Abbott Architect	34	15.0	5.1	0	4.7	4.4	2	6.2	5.5	1	42.5	4.7	1	5.9	5.1	1
Beckman Access	14	17.4	6.5	0	5.4	8.2	0	7.8	7.1	0	47.7	8.4	0	7.6	10.9	0
DxI	14	17.4	6.5	0	5.4	8.2	0	7.8	7.1	0	47.7	8.4	0	7.6	10.9	0
Roche Elecsys	98	16.3	3.1	0	5.6	3.5	0	7.1	3.0	1	47.9	3.7	1	6.4	3.7	0
E170, e601, e602, e801	91	16.3	3.0	0	5.6	3.4	0	7.1	3.0	1	47					
Siemens A Centaur	28	17.8	5.9	0	5.7	6.5	0	7.7	7.1	0	50					
Siemens Atellica	9	18.8	8.0	1	6.2	8.8	1	8.6	7.0	0	50					
Siemens I2000fam	7	16.3	3.6	1	5.2	3.1	0	6.2	4.4	0	36					
Immulite 2000, XPi	7	16.3	3.6	1	5.2	3.1	0	6.2	4.4	0	36					

Mean data for the current distribution for all methods with five or more users.

			BIAS			VAR		
		n	Median	Interquartile range		Median	Interquartile range	
All methods		211	+0.5	-7.2	+5.2	4.4	3.3	6.3
Abbott Alinity	AB20	13	-9.0	-10.4	-8.0	4.4	3.6	5.8
Abbott Architect	AB13	34	-10.9	-12.3	-8.3	4.5	3.9	5.3
Beckman Access	SF1	15	+6.8	+5.6	+9.9	7.6	6.5	9.1
DxI		15	+6.8	+5.6	+9.9	7.6	6.5	9.1
OCD (J&J) VITROS	AM12	3	-14.2	-15.1	-13.0	9.2	8.9	9.3
P E DELFIA	PH2	1	-21.4	-21.4	-21.4	12.9	12.9	12.9
AutoDELFIA		1	-21.4	-21.4	-21.4	12.9	12.9	12.9
Randox Evolution	RX4	2	-5.7	-6.8	-4.6	13.4	12.1	14.7
Roche Elecsys	BO5	98	+0.5	-0.3	+2.1	3.2	2.8	4.1
1010, 2010, e411		2	+3.6	+3.3	+3.9	3.8	3.7	3.9
E170, e601, e602, e801		92	+0.5	-0.3	+2.0	3.2	2.8	4.1
Siemens A Centaur	CO10	28	+10.4	+8.3	+12.9	6.3	5.7	
Siemens Atellica	SM20	9	+16.2	+14.5	+17.9	6.7	6.1	
Siemens I2000fam	DC11	7	-8.6	-10.3	-8.1	9.8	9.1	
Immulite 2000, XPi		7	-8.6	-10.3	-8.1	9.8	9.1	
Tosoh AIA	TO1	1	+43.3	+43.3	+43.3	4.7	4.7	

Cumulative BIAS and VAR figures for all methods.

UK NEQAS for MSS - 2nd Trimester		Laboratory :
Distribution : **358**	Date : 29-Jun-2021	Page 34 of 41
Analyte : Risk of Down's Syndrome (2nd T at term)		

UK NEQAS [Edinburgh]

Spec.	Pool	Pool description
D073	R574	Pool of first trimester pregnancy serum.
D074	R569	Pool of second trimester pregnancy serum.
D075	R575	Pool of first and second trimester pregnancy serum.

■ AFP+fb-hCG+UE3+IA

Running risk score (RRS)
+2.0
NP-SD of RRS (SDRRS)
0.0

Your cumulative scores.

Specimen : D073

	n	Median	NPCV
AFP+fb-hCG	8	1466	50
AFP+fb-hCG+UE3	7	2500	73
AFP+fb-hCG+UE3+IA	16	2894	45
AFP+t-hCG	5	1100	
AFP+t-hCG+UE3	19	1800	28
AFP+t-hCG+UE3+IA	14	10000	47

Your risk estimate 10000
Your target risk 2894
Your risk score +2.0

Specimen : D074

	n	Median	NPCV
AFP+fb-hCG	8	1048	45
AFP+fb-hCG+UE3	7	1698	65
AFP+fb-hCG+UE3+IA	16	2076	29
AFP+t-hCG	5	800	
AFP+t-hCG+UE3	19	1466	32
AFP+t-hCG+UE3+IA	14	4470	36

Your risk estimate 6361
Your target risk 2076
Your risk score +2.0

Specimen : D075

	n	Median	NPCV
AFP+fb-hCG	8	768	50
AFP+fb-hCG+UE3	7	1306	63
AFP+fb-hCG+UE3+IA	16	1695	31
AFP+t-hCG	5	696	
AFP+t-hCG+UE3	19	1300	35
AFP+t-hCG+UE3+IA	14	3188	33

Your risk estimate 2864
Your target risk 1695
Your risk score +2.0

Summary data showing median risk and spread [i.e. non-parametric estimate of the coefficient of variation (NPCV)] for all sets of analytes.

Histograms showing all risk estimates returned by users of the same set of analytes as those used in your laboratory.

Summary data for each specimen, showing your risk, the target risk and your risk score (i.e. your deviation from target).

*Each column shows your risk estimates, targets and risk scores for specimens in a single distribution.*

Pool (exclusion) [Type]	Distribution 353 09-Feb-2021 risk	target	score	Distribution 354 09-Mar-2021 risk	target	score	Distribution 355 06-Apr-2021 risk	target	score	Distribution 356 04-May-2021 risk	target	score	Distribution 357 01-Jun-2021 risk	target	score	Distribution 358 29-Jun-2021 risk	target	score
R562 [B]							5	5	+2.0									
R567 [B]				5	5	+2.0	5	5	+1.0									
R568 [B]	5	5	+2.0							5	5	+2.0						
R572 [B]				20	18	+1.0												
R570 [B]	30	58	-2.0							54	42	0.0						
R571 [B]				2206	1263	+1.0												
R575 [B]													6220	1600	+2.0	2864	1695	+2.0
R576 [B]													10000	2400	+2.0			
R563 [B]							6069	2400	+1.0									
R569 [B]	5858	2494	+2.0							6137	1743	+2.0				6361	2076	+2.0
R574 [B]													10000	3292	+2.0	10000	2894	+2.0

Pools listed in order of median risk

Enables assessment of stability of targets and risks reported for the same pool if issued more than once.

	Distribution 353	Distribution 354	Distribution 355	Distribution 356	Distribution 357	Distribution 358
Method	AFP+fb-hCG+UE3+IA	AFP+fb-hCG+UE3+IA	AFP+fb-hCG+UE3+IA	AFP+fb-hCG+UE3+IA	AFP+fb-hCG+UE3+IA	AFP+fb-hCG+UE3+IA
Med.score	2.0	1.0	1.0	2.0	2.0	2.0
RRS	+2.0	+2.0	+2.0	+2.0	+2.0	+2.0
SDRRS	0.0	0.0	0.0	0.0	0.0	0.0

B   Base pool, no additions.

Your current running risk score = +2.0

Current NP-SD of your running risk score = 0.0

Trends in your running risk score.

Trends in the non-parametric standard deviation (NP-SD) of your RRS (SDRRS).

UK NEQAS for Pregnancy Testing	Laboratory :
Distribution : **279** Date : 29-Jun-2021	Page 1 of 2
Analyte : Urinary hCG (Qualitative)	iSR08310

UK NEQAS [Edinburgh]

Spec.	Pool	Pool description / Treatments / Additions
X577	Q610	Post-menopausal female urine.
X578	Q611	Endogenous hCG diluted in Pool Q610.

Description of specimens and pools.

The pie charts in the boxes below and at left depict schematically the proportion of participants reporting negative (N), equivocal (E) or positive (P) qualitative results for the specimens in this distribution.

Consensus is reached if at least 80% of participants using kits with the same claimed detection limit submit the same result (e.g. N or P). Specimens are excluded from calculations of cumulative scoring if consensus is not reached.

Specimen : X577

☐ N	99.0 %	
◻ E	0.0 %	
■ P	1.0 %	

☐ N Your result
☐ N Consensus

Your score 0

Abbott Architect

N = Negative
E = Equivocal
P = Positive

Specimen : X578

☐ N	3.7 %	
◻ E	0.0 %	
■ P	96.3 %	

■ P Your result
■ P Consensus

Your result

Consensus

Summary of responses for the specimens in the current distributions.

Your score 0   **Your score**

Abbott Architect   **Your method**

N = Negative
E = Equivocal
P = Positive

Specimens distributed in each category

☐ N	50.0 %	(6)
◻ E	0.0 %	(0)
■ P	50.0 %	(6)

Methods, method codes and quoted detection limits.

Please refer to Table 1 in the Comments Section for methods for which results were submitted at the time of the first analysis. Method codes and quoted detection limits are also shown in Table 1.

Your interpretation for each category

Negative

☐ N	100.0 %	(6)
◻ E	0.0 %	(0)
■ P	0.0 %	(0)

Positive

☐ N	0.0 %	(0)
◻ E	0.0 %	(0)
■ P	100.0 %	(6)

Trends in your cumulative interpretation score.

Your Cumulative Interpretive Score is 0

Your scores for each specimen in the time window.

Dist	Spec	Score	Dist	Spec	Score	Dist	Spec	Score
268	X555	0	272	X563	0	276	X571	0
268	X556	0	272	X564	0	276	X572	0
269	X557	0	273	X565	0	277	X573	0
269	X558	0	273	X566	0	277	X574	0
270	X559	0	274	X567	0	278	X575	0
270	X560	0	274	X568	0	278	X576	0
271	X561	0	275	X569	0	279	X577	0
271	X562	0	275	X570	0	279	X578	0

Cumulative Interpretive Scores

The acceptable performance limit set by the National Quality Assurance Advisory Panel for Chemical Pathology is a cumulative score of less than or equal to 10. The cumulative interpretive scores have therefore been divided into 3 categories and are represented on the graph above as follows:

Desirable category (white area): Interpretive score of 0 **Acceptable category (pale grey area):** Interpretive score from 2 to 10
Unacceptable category (dark grey area): Interpretive score of >10

Summary of Scores: The right hand table above shows your score for each specimen over the 12 most recent distributions.

| Spec.	Pool	Pool description
X577	Q610	Post-menopausal female urine.
X578	Q611	Endogenous hCG diluted in Pool Q610.

☐ All methods
☐ Total hCG methods
■ Abbott Architect

Your method is
Abbott Architect

Specimen : X577

	n	Mean	GCV
All methods	7	1	34.7
Total hCG methods	7	1	34.7
Roche ElecSYS (Total)	5	1	24.9

Your result	1.26
Your target (GLTM)	1
Your deviation %	-5.7
Standard Uncertainty	0.24

Specimen : X578

	n	Mean	GCV
All methods	15	77	23.3
Total hCG methods	14	79	18.9
Roche ElecSYS (Total)	8	78	16.7

Your result	63.9
Your target (GLTM)	79
Your deviation %	-19.1
Standard Uncertainty	4.90

Summary data showing overall, method group and method means.

Histograms showing all results. Your result indicated by the arrow.

Your summary data for each specimen, showing your result, the target result and your deviation from target.

The histograms showing quantitative results are similar to those in the serum hCG scheme. Results for individual qualitative and quantitative methods are listed in the tables on the accompanying comments sheet.

Calculation of BIAS and VAR: Cumulative performance statistics

Specimen and laboratory performance statistics are calculated after logarithmic transformation of results, using the trimming method of Healy MJR (*Clin Chem* 1979; **25**: 675-677). Logarithmic transformation allows for skewness in the data and appropriate computation of errors while trimming improves the reliability of the mean and measure of scatter.

1. SPECIMEN STATISTICS

1.1 All laboratory trimmed mean (ALTM) and its geometric coefficient of variation (GCV)

For each specimen non-numeric results, including those reported as "less than" or "greater than" are discarded. All remaining individual results are ranked and transformed into their natural logarithms. The lowest and highest 5% of results (rounded up to the nearest whole number) are trimmed (Healy, 1979). The excluded results play no part in the calculation of the estimate of the mean of the results (ALTM) or the scatter of values (GCV), but **are not necessarily outliers** and are therefore retrieved for the later identification of between-laboratory, within-specimen outliers and calculations of individual laboratory BIAS and VAR (see below).

1.2 Grouped laboratory trimmed mean (GLTM) and its GCV

Calculations exactly analogous to those described above can be performed on results from groups of similar methods, such as assays of hCG classified according to recognition of the free β-subunit of hCG. The estimate of the mean is referred to as the GLTM, and its associated estimate of scatter is the GCV.

1.3 Method laboratory trimmed mean (MLTM) and its GCV

Calculations exactly analogous to those described above can be performed on results from a single method. The estimate of the mean is referred to as the MLTM, and its associated estimate of scatter is the GCV.

2. LABORATORY PERFORMANCE STATISTICS

2.1 Cumulative BIAS and its variability (VAR)

Cumulative bias (BIAS) and the variability of the bias (VAR) are calculated for each laboratory from all results returned by that laboratory on all usable specimens during the most recent six distributions (usually six months but 12 months for Peptide II).

Non-numeric results are discarded, as above, and the remaining results are transformed by taking natural logarithms. Deviations are calculated by subtracting the natural logarithm of the chosen target for the analyte in question (ALTM or GLTM) from these logarithmic values. (This is equivalent to division of untransformed values). The values are ranked and trimmed as above. The mean and LSD are calculated and within-laboratory, between-specimen outliers identified. The BIAS is then the antilog of this mean expressed as a percentage difference from 100 and the VAR is the GCV of the deviations.

3. WORKED EXAMPLE

The following gives a worked example from the prolactin NEQAS (specimen statistics) and the growth hormone NEQAS (laboratory statistics) and should be read in conjunction with Healy, 1979.

3.1 Specimen Statistics

3.1.1 Rank data, take natural logs, trim highest and lowest 5% and assign weightings. i = Rank of trimmed data, k = number of results after trimming

Lab	Raw result (mU/L)	Natural log (x)	Rank (i)	Weighting (2i-k-1)
12	260	5.5607		Trimmed
175	271	5.6021		Trimmed
1823	275	5.6167	1	24
14	278	5.6276	2	-22
272	280	5.6348	3	-20
408	280	5.6348	4	-18
39	280	5.6348	5	-16
38	280	5.6348	6	-14
17	281	5.6384	7	-12
1614	282	5.6419	8	-10
2	286	5.656	9	-8
80	288	5.663	10	-6
1	290	5.6699	11	-4
412	290	5.6699	12	-2
96	290	5.6699	13	0
86	290	5.6699	14	2
124	298	5.6971	15	4
701	298	5.6971	16	6
933	300	5.7038	17	8
48	300	5.7038	18	10
49	300	5.7038	19	12
627	303	5.7137	20	14
83	305	5.7203	21	16
1001	310	5.7366	22	18
11	310	5.7366	23	20
206	310	5.7366	24	22
216	320	5.7683	25	24
606	325	5.7838		Trimmed
74	340	5.8289		Trimmed

3.1.2 Choice of number of results to be trimmed

The number of results to be trimmed is that which would remove 10% of the sample (the lowest 5% and the highest 5%), rounded up to the next even number.

In this case, the number of raw results, n = 29, so the number trimmed is 10% of 29 = 2.9 which is rounded up to 4. Therefore, the lowest 2 results and the highest 2 results are removed. Number of results left after trimming, k = 25.

3.1.3 Calculate the ALTM

Mean trimmed, transformed results, $\bar{x} = \dfrac{\sum\limits_{i=1}^{k}(x_i)}{k} = 5.679$

$$\text{ALTM} = e^{\bar{x}} = 292.7 \text{ mU/ L}$$

Where x_i = natural logarithm of i'th untrimmed result.

k = number of results remaining after trimming.

3.1.4 Calculate proportion untrimmed

Total number of results, n = 29

Number of results after trimming, k = 25

Proportion untrimmed, $p = \dfrac{k}{n} = 0.8621$

3.1.5 Obtain unbiasing factor

This is obtained from Healy, p 676

$$b_p = 2.359$$

3.1.6 Calculate linear estimate of the standard deviation, LSD

$$\text{LSD} = \frac{b_p \times \sum\limits_{i=1}^{k}(2i - k - 1) \times x_i}{k\,(k - 0.5)}$$

In this example, k (k - 0.5) = 25 × 24.5 = 612.5

(2i - k - 1) = Weighting factor for each natural log value

Sum of products, ln(result) × weighting factor

$$= \sum_{i=1}^{k}(x_i \times \text{weight}_i) = 14.4752$$

$$\text{LSD} = \frac{2.359 \times 14.475}{612.5} = 0.05575$$

This figure is an estimate of the standard deviation of the natural log values which, in practice, is close to the figure for the proportional coefficient of variation.

Note that the LSD refers only to the log values. The antilog of the LSD is not an appropriate measure of the scatter of the raw data. To estimate the scatter we calculate the GCV (Kirkwood, TBC 1979. *Biometrics*;**35**:908-909) which is a multiplicative factor (see 3.1.7).

3.1.7 Calculate the geometric coefficient of variation

$$\text{GCV} = (\,e^{\text{LSD}} - 1) \times 100$$

$$e^{\text{LSD}} = 1.0573$$

$$\text{GCV} = 5.7\%$$

3.1.8 Identification of between-laboratory, within-sample outliers

An outlier is defined as a value outside the 99% confidence interval of the mean (of the logged results), which is approximately ± three (linear) standard deviations.

$$\text{From } (\bar{x} - (3 \times \text{LSD})) = 5.679 - 0.167 = 5.512$$

$$\text{to } (\bar{x} + (3 \times \text{LSD})) = 5.679 + 0.167 = 5.846$$

So, from section 3.1.1, we see that there are no between-laboratory, within-sample outliers. Note that trimmed results and outliers are not the same; trimmed results only become outliers if they are outside the ±3 LSD range from the mean.

3.2 Laboratory Statistics

The process is analogous to that described above, except that the starting data are an individual laboratory's results on all usable specimens obtained during the six distribution window.

3.2.1 Calculate difference of ln (lab result) from ln (target value)

Specimen Number	Target, mU/L (TV)	Lab Result, mU/L (LR)	ln(LR) - ln(TV) (Z)
H541	3.6	4.6	0.2451
H542	9.0	13.2	0.3829
H545	3.1	4.3	0.3272
H546	1.2	2.2	0.6061
H550	2.6	4.0	0.4307
H551	5.4	7.4	0.315
H552	2.5	3.2	0.2468
H553	5.2	7.9	0.4182
H554	4.3	5.1	0.1706
H555	6.4	7.5	0.1586
H556	2.6	N.R.	-
H557	6.5	7.6	0.1563
H558	5.2	7.3	0.3392
H559	4.4	5.9	0.2933
H560	5.7	8.4	0.3877
H561	6.2	6.6	0.0625
H562	6.0	7.0	0.1541
H563	5.0	6.2	0.2151
H564	2.4	2.7	0.1177
H565	4.2	4.2	0
H566	5.1	6.0	0.1625
H567	5.8	8.9	0.4281
H568	5.7	7.7	0.3007
H569	5.6	7.7	0.3184
H570	5.4	7.4	0.315

The target can be either the ALTM (as is the case for growth hormone in this example) or the appropriate GLTM (for example, for hCG).

The missing specimen numbers refer to specimens that were deemed unusable from the point of view of inclusion in the cumulative statistics. N.R. indicated that the lab did not return a result. Having obtained these differences (which are, as noted above, actually the logs of {result divided by target}), the calculation proceeds exactly as above.

3.2.2 Rank and trim deviations. Calculate mean (BIAS), LSD (GCV) and identify outliers

Z	Weight
0	Trimmed
0.0625	Trimmed
0.1177	-19
0.1541	-17
0.1563	-15
0.1586	-13
0.1625	-11
0.1706	-9
0.2151	-7
0.2451	-5
0.2468	-3
0.2933	-1
0.3007	1
0.315	3
0.315	5
0.3184	7
0.3272	9
0.3392	11
0.3829	13
0.3877	15
0.4182	17
0.4281	19
0.4307	Trimmed
0.6061	Trimmed

n = 24, k = 20
Proportion untrimmed, p = 0.8333
Unbiasing factor, b_p = 2.477

Mean of logs of trimmed values, $\bar{z}$

$$= \frac{\sum_{i=1}^{k} z}{k} = 0.2726$$

$$BIAS = (e^{\bar{z}} - 1) \times 100 = 31.3\%$$

$$k\ (k - 0.5) = 20 \times 19.5 = 390$$

$$LSD = \frac{b_p \times \sum_{i=1}^{k} (2i - k - 1) \times z_i}{k\ (k - 0.5)}$$

$$= 0.136$$

The GCV of the BIAS (the VAR) = $(e^{LSD} - 1) \times 100 = 14.6\%$

Limits for outliers are $(\bar{z} \pm 3\,LSD) = (-0.351\ to\ +0.681)$

So there are no within- laboratory, between- specimen outliers.

Therefore the laboratory cumulative performance in the six distribution window is described as

BIAS 31.3%

VAR 14.6%

No outlier results

Calculation of risk scores

(Maternal serum screening)

Protocol: Set of analyses that a laboratory uses to derive risk, e.g. "AFP and total hCG", "AFP, free β-hCG and UE3", etc.

Specimen statistics (At least five risk estimates are required to calculate these)

Target risk: The median of all risks returned on a given specimen by users of your protocol.

Non-parametric estimate of standard deviation (NPSD): This is the median of the absolute differences between each risk for a given protocol and the target risk. It is approximately 80% of the SD calculated in the usual fashion.

Non-parametric estimate of the coefficient of variation (NPCV): The NPSD expressed as a percentage of the target risk.

Risk score (RS): Designed to be analogous to bias. Ideally, your RS should be zero. All risks on a given specimen for users of your protocol are arranged in order and divided into five bins, each covering 20 percentiles. Your RS is assigned according to which band your risk falls into:

Centile band	Risk score (RS)
< 20	-2
20 - 40	-1
> 40 - 60	0
> 60 - 80	+1
> 80	+2

Running risk score (RRS): Designed to be analogous to BIAS. It is the median of your risk scores recorded during the time window (most recent six distributions). Ten risk scores are needed to calculate RRS. Your RRS should be close to zero.

Non-parametric estimate of the SD of your RRS (SDRRS): Designed to be analogous to VAR. It is the non-parametric SD of your RRS. Calculated as the median of the absolute differences between your RS and RRS. Your SDRRS should be close to zero.

Calculation of qualitative scores

(Pregnancy testing)

Score (for a specimen)

Your reported result for each specimen is scored against the method group consensus and given a score of 0, 2 or 10 by reference to the following "look-up" table:

		Consensus result		
		N	E	P
Your result	N	0	2	10
	E	2	0	2
	P	10	2	0

Where "N" = Negative, "E" = Equivocal and "P" = Positive. For example, if the consensus result is "N" but your result is "P", then your score is 10.

Cumulative interpretative score is calculated by the addition of your scores for each of the specimens in the current six distributions. At least six usable results are required.

Conditions of participation in UK NEQAS (UK clinical laboratories)

BIAS and VAR performance criteria

Specialist Advisory Group membership

Steering Committee and Advisory Panel (NQAAP) membership

Useful addresses

Appendix 1

JOINT WORKING GROUP FOR QUALITY ASSURANCE: CONDITIONS OF EQA SCHEME PARTICIPATION (UK clinical laboratories)

Effective from October 2010

The Joint Working Group for Quality Assurance (JWG) is a multidisciplinary group accountable to the Royal College of Pathologists for the oversight of performance in external quality assurance schemes (EQA) in the UK. Membership consists of the Chairmen of the National Quality Assurance Advisory Panels (NQAAPs), and representatives from the Institute of Biomedical Sciences, the Independent Healthcare Sector, the Department of Health and the United Kingdom Accreditation Service (UKAS). The JWG has established the following conditions, that apply to any laboratory offering a service to patients in the United Kingdom directly or indirectly (e.g. by generating data for the Committee on Safety of Medicines or for medical research).

1. The Head of a laboratory is responsible for registering the laboratory with an appropriate accredited EQA scheme.

2. The laboratory should be registered with available EQA schemes to cover all the tests that the laboratory performs as a clinical service.

3. EQA samples must be treated in exactly the same way as clinical samples. If this is not possible because of the use of non-routine material for the EQA (such as photographs) they should still be given as near to routine treatment as possible.

4. Changes in the test methodology of the laboratory should be notified in writing to the appropriate scheme organiser and should be reflected in the EQA schemes with which the laboratory is registered.

5. Samples, reports and routine correspondence may be addressed to a named deputy, but correspondence from Organisers and NQAAPs concerning persistent poor performance (red - see below) will be send directly to the Head of the laboratory or, in the case of the independent healthcare sector, the Hospital Executive Director.

6. The EQA code number and name of the laboratory and the assessment of individual laboratory performance are confidential to the participant and will not be released by Scheme Organisers without the written permission of the Head of the laboratory to any third party other than the Chairman and members of the appropriate NQAAP and the Chairman and members of the JWG. The identity of a participant (name of laboratory and Head of Department) and the tests and EQA schemes for which that laboratory is registered (but not details of performance) may also be released by the Scheme Organiser on request to the Health Authority, Hospital Trust/Private Company in which the laboratory is situated after a written request has been received.

7. A NQAAP may, with the written permission of the Head of a laboratory, correspond with the Authority responsible for the laboratory, about deficiencies in staff or equipment which, in the opinion of the NQAAP members, prevent the laboratory from maintaining a satisfactory standard.

8. Laboratories' EQA performance will be graded using a traffic light system; green will indicate no concerns, amber poor performance, red persistent poor performance, with black being reserved for the tiny number of cases that cannot be managed by the Organiser or NQAAP and that have to be referred to the JWG. The criteria for poor performance (amber) and persistent poor performance (red) are proposed by the EQA scheme Steering Committee in consultation with the EQA Provider/Scheme Organiser and approved by the relevant NQAAP.

9. When a laboratory shows poor (amber) performance the Organiser will generally make contact with the participant in accordance with the Scheme Standard Operating Procedure for poor performance. Within two weeks of a laboratory being identified as a persistent poor performer (red) the Organiser will notify the Chairman of the appropriate NQAAP together with a résumé of remedial action taken or proposed. The identity of a persistently poorly performing laboratory (red) will be made available to members of the NQAAP and JWG. The NQAAP Chairman should agree in writing any remedial action to be taken and the timescale and responsibility for carrying this out; if appropriate this letter will be copied to accreditation/reregulate bodies such as UKAS and HFEA who may arrange an urgent visit to the laboratory. Advice is offered to the Head of the laboratory in writing or, if appropriate, a visit to the Laboratory from a NQAAP member or appropriate agreed expert may be arranged.

10. If persistent poor performance remains unresolved, the NQAAP Chairman will submit a report to the Chairman of the JWG giving details of the problem, its causes and the reasons for failure to achieve improvement. The Chairman of the JWG will consider the report and, if appropriate, seek specialist advice from a panel of experts from the appropriate professional bodies to advise him/her on this matter. The Chairman of the JWG will be empowered to arrange a site meeting of this panel of experts with the Head of the Department concerned. If such supportive action fails to resolve the problems and, with the agreement of the panel of experts, the Chairman of the JWG will inform the Chief Executive Officer, or nearest equivalent within the organisation of the Trust or Institution of the problem, the steps which have been taken to rectify it and, if it has been identified, the cause of the problem. The Chairman of the JWG also has direct access and responsibility to the Professional Standards Unit of the Royal College of Pathologists. Should these measures fail to resolve the issues, the laboratory will be referred to the Care Quality Commission for further action.

11. Problems relating to EQA Schemes, including complaints from participating laboratories, which cannot be resolved by the appropriate Organiser, Steering Committee or NQAAP, will be referred to the Chairman of the JWG.

Joint Working Group for Quality Assurance Conditions of EQA Scheme Participation, August 2010

[Available on the website of the Royal College of Pathologists, www.recpath.org; "document July 2015"; accessed November 19th 2022.]

Appendix 2

BIAS and VAR Performance Criteria [Reviewed March 2021]

(Subject to revision)

Scheme	Analytes	BIAS (+/- %)	VAR (%)
Peptide hormones I	FSH	20	15
	LH	20	15
	AMH	20	15
	Prolactin	20	15
	hGH	20	20
Peptide hormones II	PTH	25	25
	ACTH	25	25
	hCT	20	25
Tumour markers	AFP	10	10
	CEA	20	20
	hCG	20	20
Pregnancy testing	(Qualitative)	Interpretation score ≤10	
Second trimester maternal serum screening [Concentrations and MoMs]	AFP	10	10
	Total hCG	10	10
	hCGβ subunit	10	10
	UE3	20	15
	Inhibin-A	n.a.	n.a.
First trimester maternal serum screening [Concentrations and MoMs]	hCGβ subunit	20	15
	PAPP-A	10	15
Pre-eclampsia markers* [Serum scheme]	PLGF	25	15
	sFlt1	25	15
Liver fibrosis markers*	PIIINP	10	10
	Hyaluronic acid	10	10
	TIMP-1	10	10
	ELF score	10	10

*Fully established UK NEQAS schemes but not yet accredited by UKAS.

Return Rate

Regular return of results is important, and failure to return results for three consecutive distributions constitutes poor performance.

Appendix 3

UK NEQAS Specialist Advisory Group for Immunoassay

Dr C Evans	Chairman
Dr G Wark	Secretary* and Organiser, UK NEQAS [Guildford]
Dr L Bailey	Expert member
Dr J Barth	Expert member
Dr P Collinson	Expert member
Dr N Elkin	Director, UK NEQAS [Glasgow]
Professor W Fraser	Expert member
Dr K Gordon	Expert member
Dr D Halsall	Expert member
Professor B Keevil	Expert member
Dr J Hawley	Expert member
Mr F MacKenzie	Director, UK NEQAS [Birmingham]
Dr M Moore	NIBSC liaison
Professor J Newell-Price	Expert member
Dr O Okosieme	Expert member
Dr L Owen	Expert member
Ms D Patel	Director, UK NEQAS [Sheffield]
Dr L Perry	Expert member
Mr A Reid	Expert member
Professor M Strachan	Expert member
Dr C Sturgeon	Director, UK NEQAS [Edinburgh]
Mr N Unsworth	Deputy Director, UK NEQAS [Edinburgh]

UK NEQAS Specialist Advisory Group for Maternal Serum Screening

Professor K Spencer	Chairman
Mrs K Donalson	Expert member
Dr C Evans	Expert member
Mr W Huttly	Expert member
Dr C Sturgeon	Director, UK NEQAS [Edinburgh]
Mr S Turner	Expert member
Mr N Unsworth	Deputy Director, UK NEQAS [Edinburgh]
Professor D Wright	Director, Down's Quality Assurance Advisory Service (DQASS)

Appendix 4

National Quality Assurance Advisory Panel (NQAAP) for Chemical Pathology

Dr Phillip Monaghan	Chair
Dr Berenice Lopez	Interim Chair, Quality Assurance in Pathology Committee (formerly Joint Working Group for Quality Assurance)
Dr David James	Chemical Pathology
Dr Ian Bailey	Association of Clinical Pathologists representative
Dr Jamie West	IBMS Representative
Dr Rachel Still	Association of Clinical Biochemists

Appendix 5

Useful addresses

UK NEQAS for Cardiac Markers	Dr Naomi Elkin Department of Laboratory Medicine Queen Elizabeth University Hospital 1345 Govan Road Glasgow G51 4TF Tel: +44 (0) 141 440 2888 E-mail: info@ukneqas-cm.org.uk
UK NEQAS for Clinical Chemistry UK NEQAS for Thyroid Hormones UK NEQAS for Steroid Hormones, Urinary Free Cortisol and SHBG	Mr Finlay Mackenzie Birmingham Quality PO Box 3909 Birmingham B15 2UE Tel: +44 (0)121 414 7300 Fax: +44 (0)121 414 1179 E-mail: birminghamquality@uhb.nhs.uk
UK NEQAS for Insulin, Growth Factors and Gastrin	Dr Gwen Wark Clinical Laboratory Royal Surrey County Hospital Edgerton Road, Guildford Surrey GU2 5XX Tel: +44 (0)1483 406715 Fax: +44 (0)1483 464168 E-mail: gwen.wark@nhs.net
UK NEQAS for Immunology, Immunochemistry & Allergy	Mrs Dina Patel Department of Immunology PO Box 894 Sheffield, S5 7YT Tel: +44 (0)114 271 5716 E-mail: dpatel@immqas.org.uk
UK NEQAS Central Office	Mrs Julie Gelder PO Box 401 Sheffield, S5 7YZ Tel: +44 (0)114 261 1689 E-mail: centraloffice@ukneqas.org
UK Accreditation Service	UKAS 2 Pine Trees Chertsey Lane Staines-upon-Thames Middlesex TW18 3HR Tel: +44 (0) 1784 429000 E-mail: info@ukas.com http://www.ukas.com
National Institute for Biological Standards and Control	NIBSC Blanche Lane South Mimms, Potters Bar Hertfordshire, EN6 3QG Tel: +44 (0) 1707 641000 E-mail: enquiries@nibsc.org www.nibsc.org/

UK NEQAS [Edinburgh] website: www.edqas.org